TY - JOUR
T1 - Analysis of two topotecan treatment schedules in patients with recurrent ovarian cancer
AU - Bruchim, Ilan
AU - Ben-Harim, Zipi
AU - Piura, Ettie
AU - Haran, Gabi
AU - Fishman, Ami
N1 - Publisher Copyright:
© 2016 Edizioni Scientifiche per l'Informazione su Farmaci e Terapia.
PY - 2016/3/3
Y1 - 2016/3/3
N2 - Two topotecan treatment schedules in patients with recurrent epithelial ovarian cancer were evaluated. Protocol A (21 days) was 1.5 mg/m2/day topotecan on days 1 through 5 of a 21-day cycle; Protocol B (weekly) 4 mg/m2 on days 1, 8, and 15 of a 28-day cycle. Efficacy was determined by clinical exam, CT scan, and CA125 levels. Forty-three patients on Protocol A and 21 on Protocol B were evaluated. As second-line treatment, Protocol A response was 9/20 (45%). Response to Protocol B was 4/17 (23.5%; NS). As third line or more, the response on Protocols A and B together was only 3/27 (11%). High-grade haematological toxicity was reported in 12/43 (27.9%) on Protocol A and 1/21 (4.8%) on Protocol B (p = 0.04). There was no difference in progression-free-intervals between schedules in second-line treatment. The weekly protocol had lower severe haematological toxicity. Clinical response in third line or more was very low.
AB - Two topotecan treatment schedules in patients with recurrent epithelial ovarian cancer were evaluated. Protocol A (21 days) was 1.5 mg/m2/day topotecan on days 1 through 5 of a 21-day cycle; Protocol B (weekly) 4 mg/m2 on days 1, 8, and 15 of a 28-day cycle. Efficacy was determined by clinical exam, CT scan, and CA125 levels. Forty-three patients on Protocol A and 21 on Protocol B were evaluated. As second-line treatment, Protocol A response was 9/20 (45%). Response to Protocol B was 4/17 (23.5%; NS). As third line or more, the response on Protocols A and B together was only 3/27 (11%). High-grade haematological toxicity was reported in 12/43 (27.9%) on Protocol A and 1/21 (4.8%) on Protocol B (p = 0.04). There was no difference in progression-free-intervals between schedules in second-line treatment. The weekly protocol had lower severe haematological toxicity. Clinical response in third line or more was very low.
KW - Chemotherapy
KW - Epithelial ovarian cancer
KW - Topotecan
UR - http://www.scopus.com/inward/record.url?scp=84978397838&partnerID=8YFLogxK
U2 - 10.1080/1120009X.2015.1115195
DO - 10.1080/1120009X.2015.1115195
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 27093640
AN - SCOPUS:84978397838
SN - 1120-009X
VL - 28
SP - 129
EP - 134
JO - Journal of Chemotherapy
JF - Journal of Chemotherapy
IS - 2
ER -
